

NOV. 22. 2005 4:36PM AVENTIS US PAT DEPT
TO: US CENTRALIZED USPTO

RECEIVED
CENTRAL FAX CENTER NO. 9958 P. 1

NOV 22 2005

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission


4

Application Number	10/749,631
Filing Date	December 31, 2003
First Named Inventor	Heinz-Werner KLEEMANN et al.
Art Unit	1626
Examiner Name	ANDERSON, Rebecca L.
Attorney Docket Number	DEAV2002/0094 US CNT

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmitted Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Response to Restriction Requirement
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Joseph Rossi		
Date	November 22, 2005	Reg. No.	47,038

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300 ; Total No. of Pages Transmitted: 4)

Signature			
Typed or printed name	Renee McGinnis	Date	November 22, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NOV. 22. 2005 4:36PM AVENTIS US PAT DEPT
DEAV2002/0094 US CNT

RECEIVED
CENTRAL FAX CENTER

NO. 9958 P. 2

NOV 22 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Heinz-Werner Kleeman

Examiner: R. Anderson

Application No.: 10/749,631

Art Unit: 1626

Filed: December 31, 2003

I hereby certify that this correspondence, along with
any referred to as filed, submitted, or enclosed
herewith, is being transmitted via facsimile to the
Commissioner for Patents, Washington, D.C. 20231,
at 571-273-8300, on

November 22, 2005

Date of Deposit

Renee McGinnis

Title: 3-Guanidinocarbonyl-1-heteroaryl-indole
Derivatives, Preparation process, Their
Use as Medicaments, and
Pharmaceutical Compositions
Comprising Them

Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT


Dear Sirs:

In response to the Restriction Requirement dated October 25, 2005 ("the Action"),

Applicants submit as follows:

Applicants hereby elect Group I, i.e., claims 1 to 6, 20, and 33, drawn to products of
formula (I).

The Action also requests an election of species for a particular species of the
compound represented by formula I. In response, Applicants hereby elect the species 3-
guanidinocarbonyl-1-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-indole hydrochloride,



, which is the subject of Example 7 at page 33 of the present specification.

Applicants reserve the right to pursue the non-elected subject matters in one or more divisional applications prior to issuance of a patent on the instant application.

If the present restriction requirement is maintained, Applicants request respectfully that, upon identification of allowable subject matter of the elected product claims, the non-elected method of treating claims commensurate in scope with the allowed product claims be rejoined in accordance with MPEP § 821.04. If such should occur, Applicants request the opportunity to further amend the rejoined method claims prior to their examination.